carmustine has been researched along with Plasmacytoma in 16 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Plasmacytoma: Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone." | 5.04 | Combination therapy for myelomatosis. ( Azam, L; Delamore, IW, 1974) |
| "One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved." | 1.30 | Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. ( Chen, MG; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Kyle, RA; Lacy, MQ; Litzow, MR; Lust, JA; Pineda, AA; Tefferi, A; Witzig, TE, 1999) |
| "Murine LPC-1 plasmacytoma is sensitive to treatment with cyclophosphamide (CY), and animals bearing this tumor in advanced stages can be cured with doses as small as 60 mg/kg." | 1.26 | Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line. ( Frondoza, CG; Humphrey, RL; Trivedi, SM, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (68.75) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Mouhieddine, TH | 1 |
| Barlogie, B | 1 |
| Teruya-Feldstein, J | 1 |
| Hou, TY | 1 |
| Dai, MS | 1 |
| Kao, WY | 1 |
| Grussendorf, M | 2 |
| Waldherr, R | 1 |
| Seelig, HP | 1 |
| Ritz, E | 1 |
| Frondoza, CG | 1 |
| Trivedi, SM | 1 |
| Humphrey, RL | 1 |
| Clemens, MR | 1 |
| Frank, H | 1 |
| Remmer, H | 1 |
| Waller, HD | 1 |
| Ghanta, VK | 1 |
| Hiramoto, RN | 1 |
| Davis, DW | 1 |
| Hiramoto, NS | 1 |
| Antonijevic, N | 1 |
| Radosevic-Radojkovic, N | 1 |
| Colovic, M | 1 |
| Jovanovic, V | 1 |
| Rolovic, Z | 1 |
| Colović, MD | 1 |
| Janković, GM | 1 |
| Colović, RB | 1 |
| Martinović-Cemerikić, VM | 1 |
| Gertz, MA | 1 |
| Lacy, MQ | 1 |
| Inwards, DJ | 1 |
| Chen, MG | 1 |
| Pineda, AA | 1 |
| Gastineau, DA | 1 |
| Greipp, PR | 1 |
| Lust, JA | 1 |
| Tefferi, A | 1 |
| Witzig, TE | 1 |
| Kyle, RA | 1 |
| Litzow, MR | 1 |
| Fremiotti, A | 1 |
| Castellani, R | 1 |
| Barbatano, L | 1 |
| Salerno, L | 1 |
| Bartolini, M | 1 |
| Obrecht, JP | 1 |
| Hiramoto, R | 1 |
| Ghanta, V | 1 |
| Durant, JR | 1 |
| Stanislawski, M | 1 |
| Rousseau, V | 1 |
| Goavec, M | 1 |
| Ito, H | 1 |
| Berko, R | 1 |
| Seissman, K | 1 |
| Colvin, M | 1 |
| Bocian, RC | 1 |
| Ben-Efraim, S | 1 |
| Dray, S | 1 |
| Azam, L | 1 |
| Delamore, IW | 1 |
| Wheeler, GP | 1 |
| Alexander, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA[NCT00002630] | Phase 2 | 50 participants (Anticipated) | Interventional | 1993-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for carmustine and Plasmacytoma
| Article | Year |
|---|---|
Combination therapy for myelomatosis.
Topics: Bone Marrow Examination; Calcium; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Thera | 1974 |
15 other studies available for carmustine and Plasmacytoma
| Article | Year |
|---|---|
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bo | 2020 |
Testicular plasmacytoma with bone dissemination without medullary plasmacytosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2003 |
[Systemic light-chain disease as a complication of plasmacytoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Bone Marrow Cells; Carmustine; | 1984 |
Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line.
Topics: Animals; Carmustine; Cell Division; Cell Line; Clone Cells; Cyclophosphamide; DNA, Neoplasm; Drug Re | 1982 |
Vinylchloride: decomposition product of BCNU in vivo and in vitro.
Topics: Breath Tests; Carmustine; Chemical Phenomena; Chemistry; Drug Stability; Gas Chromatography-Mass Spe | 1982 |
Maintenance of MOPC 104E myeloma in plateau phase.
Topics: Animals; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dose-Response Relationship, | 1980 |
Multifocal plasmacytoma of hand and foot bones.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Combined Modality | 1996 |
Non-secretory solitary plasmacytoma of the spleen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Male; Melphala | 1998 |
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow; Carm | 1999 |
[Interim results of the combination of M2 polychemotherapy with calcitonin and synthetic anabolic agents in the treatment of plasmacytoma].
Topics: Aged; Anabolic Agents; Antineoplastic Agents; Calcitonin; Carmustine; Cyclophosphamide; Dihydrotesto | 1979 |
[Results of plasmacytoma therapy of ALGB (acute leukemia group B)].
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; M | 1976 |
Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Line; Cell Survival; Cyclophosphamide; Disease Mode | 1975 |
Immunotoxins containing glucose oxidase and lactoperoxidase with tumoricidal properties: in vitro killing effectiveness in a mouse plasmacytoma cell model.
Topics: Animals; Bone Marrow; Buthionine Sulfoximine; Carmustine; Dose-Response Relationship, Immunologic; D | 1989 |
Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late stage MOPC-315 plasmacytoma.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Carmustine; Cell Division; Cyclophosphamide; | 1988 |
Duration of inhibition of synthesis of DNA in tumors and host tissues after single doses of nitrosoureas.
Topics: Animals; Bone Marrow; Brain; Carmustine; Cricetinae; Cyclohexanes; Depression, Chemical; DNA, Neopla | 1974 |